Pharma BD Deal Intelligence

Mylan Inc. / Agila Specialties (Strides Arcolab)

2013 · Acquisition/Merger · $1.8B · Complete

Announcement Sentiment

Positive

Mylan to acquire Agila Specialties from Strides Arcolab for $1.6B cash + up to $250M contingent ($1.75B total); created leading global injectables platform.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Dilutive

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Feb 27, 2013
Closed Dec 04, 2013
Deal value $1.8B
Deal type Acquisition/Merger
Therapeutic area Generic injectables
Indications Generic injectables
Key assets Generic injectables platform (700+ marketed products, 350+ pipeline)
Mechanism Mixed generic injectable portfolio

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals